From Surf Wiki (app.surf) — the open knowledge base

MDMAI

Chemical compound

| elimination_half-life =

MDMAI, also known as 5,6-methylenedioxy-N-methyl-2-aminoindane, is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic serotonin releasing agent (SRA) in animals and is a putative entactogen in humans.

Interactions

History

MDMAI was first described in the scientific literature by David E. Nichols and colleagues in 1990.

Chemistry

MDMAI can be thought of as a cyclized analogue of MDMA where the α-methyl group of the alkylamino side chain has been joined back round to the 6-position of the aromatic ring to form an indane ring system. This changes the core structure of the molecule from phenethylamine to 2-aminoindane, and causes the pharmacological properties of the two compounds to be substantially different.

References

(2011). "Aminoindanes--the next wave of 'legal highs'?". Drug Test Anal.
(1990). "(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity". J Pharmacol Exp Ther.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

2-aminoindanes david-e.-nichols designer-drugs entactogens methylenedioxyphenethylamines serotonin-releasing-agents

Want to explore this topic further?

Ask Mako anything about MDMAI — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report